Insider Selling: Sera Prognostics (NASDAQ:SERA) Insider Sells 8,024 Shares of Company Stock

by · The Markets Daily

Sera Prognostics, Inc. (NASDAQ:SERA – Get Free Report) insider Tiffany Eul Davis Inglis sold 8,024 shares of the stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $2.03, for a total value of $16,288.72. Following the transaction, the insider owned 83,565 shares of the company’s stock, valued at $169,636.95. This represents a 8.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tiffany Eul Davis Inglis also recently made the following trade(s):

  • On Thursday, September 10th, Tiffany Eul Davis Inglis sold 486 shares of Sera Prognostics stock. The shares were sold at an average price of $2.00, for a total transaction of $972.00.

Sera Prognostics Trading Down 1.4%

Shares of SERA stock traded down $0.03 on Tuesday, reaching $2.04. The company’s stock had a trading volume of 4,687 shares, compared to its average volume of 45,591. The stock’s fifty day simple moving average is $2.04 and its 200-day simple moving average is $2.02. Sera Prognostics, Inc. has a 1 year low of $1.56 and a 1 year high of $3.95. The company has a market capitalization of $80.48 million, a price-to-earnings ratio of -3.04 and a beta of 1.06.

Sera Prognostics (NASDAQ:SERA – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.07 million. Sera Prognostics had a negative net margin of 47,475.72% and a negative return on equity of 46.71%. Equities research analysts forecast that Sera Prognostics, Inc. will post -0.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $5.50.

View Our Latest Analysis on Sera Prognostics

Institutional Investors Weigh In On Sera Prognostics

Large investors have recently added to or reduced their stakes in the stock. Arkadios Wealth Advisors purchased a new stake in Sera Prognostics during the first quarter valued at approximately $25,000. Segall Bryant & Hamill LLC bought a new stake in shares of Sera Prognostics in the 1st quarter valued at approximately $193,000. Finally, AWM Investment Company Inc. bought a new stake in shares of Sera Prognostics in the 2nd quarter valued at approximately $377,000. 54.64% of the stock is owned by institutional investors.

Sera Prognostics Company Profile

(Get Free Report)

Sera Prognostics, Inc is a women’s health diagnostics company focused on improving pregnancy outcomes through biomarker-based testing. The company develops and commercializes blood tests designed to identify women at elevated risk for pregnancy complications, particularly spontaneous preterm birth.

Its lead product, the PreTRM Test, is a blood-based test that analyzes proteins associated with pregnancy and provides an individualized risk assessment for spontaneous preterm birth in singleton pregnancies.

Featured Articles